Tearsheet

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow


0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 12%, Dividend Yield is 7.7%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 8.2%, FCF Yield is 6.4%
Weak multi-year price returns
2Y Excs Rtn is -43%
Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 1.0%, Rev Chg QQuarterly Revenue Change % is -2.9%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16%
  
2 Low stock price volatility
Vol 12M is 31%
  
3 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine. Themes include Clinical Communication & Workflow Optimization.
  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 12%, Dividend Yield is 7.7%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 8.2%, FCF Yield is 6.4%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16%
2 Low stock price volatility
Vol 12M is 31%
3 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine. Themes include Clinical Communication & Workflow Optimization.
4 Weak multi-year price returns
2Y Excs Rtn is -43%
5 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 1.0%, Rev Chg QQuarterly Revenue Change % is -2.9%

Valuation, Metrics & Events

SPOK Stock


Why The Stock Moved


Qualitative Assessment

AI Generated Analysis | Feedback

1. Spok Holdings (SPOK) missed analyst expectations for both earnings per share (EPS) and revenue in its third-quarter 2025 financial report, which was released on October 29, 2025. 2. The company reported Q3 2025 EPS of $0.15, falling short of the consensus estimate of $0.19 per share, and revenue of $33.87 million, which was below the analyst consensus estimate of $35.90 million.

Show more

Stock Movement Drivers

Return vs. Risk


Price Returns Compared

 202020212022202320242025Total [1]
Returns
SPOK Return-4%-12%3%108%12%-11%79%
Peers Return16%31%-20%20%19%8%84%
S&P 500 Return16%27%-19%24%23%16%111%

Monthly Win Rates [3]
SPOK Win Rate50%33%58%75%58%50% 
Peers Win Rate58%63%33%58%58%48% 
S&P 500 Win Rate58%75%42%67%75%73% 

Max Drawdowns [4]
SPOK Max Drawdown-28%-33%-27%0%-6%-16% 
Peers Max Drawdown-25%-6%-34%-9%-8%-19% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 


[1] Cumulative total returns since the beginning of 2020
[2] Peers: SYK, BAX, ORCL, MSFT, CSCO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/12/2025 (YTD)

How Low Can It Go

Unique KeyEventSPOKS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-50.9%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven103.5%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven307 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-29.2%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven41.2%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven296 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-50.6%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven102.3%24.7%
2018 CorrectionTime to BreakevenTime to BreakevenNot Fully Recovered days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-74.8%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven296.8%131.3%
2008 Global Financial CrisisTime to BreakevenTime to BreakevenNot Fully Recovered days1480 days

Compare to OMCL, MDRX, BEAT, CARL, HTFL


In The Past

Spok's stock fell -50.9% during the 2022 Inflation Shock from a high on 1/6/2021. A -50.9% loss requires a 103.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Spok (SPOK)

Better Bets than Spok (SPOK)

Latest Trefis Analyses

TitleTopic
0DASHBOARDS 
1How Low Can Spok Stock Really Go?Return
Title
0ARTICLES

Trade Ideas

Select past ideas related to SPOK. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
15.0%15.0%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-5.1%-5.1%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
9.0%9.0%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
2.3%2.3%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
16.0%16.0%-5.1%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
15.0%15.0%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-5.1%-5.1%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
9.0%9.0%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
2.3%2.3%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
16.0%16.0%-5.1%

Recent Active Movers

Recent Active Movers

More From Trefis

Peer Comparisons for Spok

Peers to compare with:

Financials

SPOKSYKBAXORCLMSFTCSCOMedian
NameSpok Stryker Baxter I.Oracle MicrosoftCisco Sy. 
Mkt Price13.31354.0919.15189.97478.5377.80133.88
Mkt Cap0.3135.49.8805.53,556.9307.8221.6
Rev LTM14024,38111,02361,017293,81257,69641,038
Op Inc LTM214,78541119,490135,93712,9918,888
FCF LTM234,073230-13,18178,01712,7332,152
FCF 3Y Avg233,2826572,15571,30213,8792,718
CFO LTM264,83274922,296147,03913,7449,288
CFO 3Y Avg263,9521,14819,874121,38414,7369,344

Growth & Margins

SPOKSYKBAXORCLMSFTCSCOMedian
NameSpok Stryker Baxter I.Oracle MicrosoftCisco Sy. 
Rev Chg LTM1.5%11.0%3.9%11.1%15.6%8.9%9.9%
Rev Chg 3Y Avg1.0%10.8%-4.5%9.8%13.2%3.7%6.8%
Rev Chg Q-2.9%10.2%5.0%14.2%18.4%7.5%8.9%
QoQ Delta Rev Chg LTM-0.7%2.4%1.2%3.4%4.3%1.8%2.1%
Op Mgn LTM14.8%19.6%3.7%31.9%46.3%22.5%21.1%
Op Mgn 3Y Avg14.8%19.5%3.6%30.8%44.6%24.2%21.8%
QoQ Delta Op Mgn LTM-0.4%0.0%0.1%0.3%0.6%0.4%0.2%
CFO/Rev LTM18.5%19.8%6.8%36.5%50.0%23.8%21.8%
CFO/Rev 3Y Avg19.0%17.8%11.6%35.5%47.2%26.1%22.6%
FCF/Rev LTM16.2%16.7%2.1%-21.6%26.6%22.1%16.4%
FCF/Rev 3Y Avg16.4%14.7%6.7%5.1%28.0%24.6%15.6%

Valuation

SPOKSYKBAXORCLMSFTCSCOMedian
NameSpok Stryker Baxter I.Oracle MicrosoftCisco Sy. 
Mkt Cap0.3135.49.8805.53,556.9307.8221.6
P/S2.55.81.113.213.15.35.6
P/EBIT17.229.5229.5-29.619.729.5
P/E21.448.0-34.352.236.729.833.2
P/CFO13.829.315.636.126.222.424.3
Total Yield12.3%3.0%0.6%2.6%3.4%5.5%3.2%
Dividend Yield7.7%0.9%3.5%0.7%0.6%2.1%1.5%
FCF Yield 3Y Avg7.2%2.6%3.7%-2.3%6.0%3.7%
D/E0.00.10.8-0.00.10.1
Net D/E-0.00.10.7--0.00.00.0

Returns

SPOKSYKBAXORCLMSFTCSCOMedian
NameSpok Stryker Baxter I.Oracle MicrosoftCisco Sy. 
1M Rtn-3.8%-5.2%2.5%-12.7%-4.9%0.5%-4.3%
3M Rtn-22.0%-7.4%-20.1%-34.9%-6.0%17.6%-13.8%
6M Rtn-14.9%-5.7%-37.0%-11.4%1.1%22.9%-8.6%
12M Rtn-13.6%-4.6%-35.7%10.7%7.8%36.1%1.6%
3Y Rtn114.4%43.7%-60.5%141.0%90.5%72.3%81.4%
1M Excs Rtn-4.2%-3.3%2.8%-16.0%-5.9%5.5%-3.7%
3M Excs Rtn-25.2%-9.1%-22.7%-40.2%-10.2%13.6%-16.4%
6M Excs Rtn-29.2%-20.0%-51.2%-25.6%-13.1%8.6%-22.8%
12M Excs Rtn-27.0%-19.8%-51.1%-5.2%-4.4%22.8%-12.5%
3Y Excs Rtn43.3%-22.9%-134.1%76.7%27.0%2.7%14.8%

Financials

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Clinical communications and collaboration solutions139    
Hardware 2234
License 7659
Maintenance 37383940
Paging revenue 73768085
Product and other revenue 2343
Professional services 13171819
Subscription   00
Total139135142148160


Price Behavior

Short Interest

Short Interest: As Of Date11282025
Short Interest: Shares Quantity345,238
Short Interest: % Change Since 1115202537.3%
Average Daily Volume189,022
Days-to-Cover Short Interest1.83
Basic Shares Quantity20,590,924
Short % of Basic Shares1.7%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
10/29/2025-12.5%-13.5%-15.3%
7/30/20257.7%7.9%7.1%
2/26/20252.4%-1.1%1.4%
10/30/20244.3%12.3%12.0%
7/24/2024-6.5%-6.9%-10.0%
2/21/20249.3%13.2%9.3%
10/25/20231.9%6.4%22.9%
2/22/20230.0%14.4%13.7%
...
SUMMARY STATS   
# Positive91012
# Negative1097
Median Positive2.4%7.1%10.7%
Median Negative-5.3%-6.9%-9.0%
Max Positive9.3%14.4%22.9%
Max Negative-13.5%-13.5%-15.3%

SEC Filings

Expand for More

Report DateFiling DateFiling
93020251030202510-Q 9/30/2025
6302025731202510-Q 6/30/2025
3312025501202510-Q 3/31/2025
12312024227202510-K 12/31/2024
93020241031202410-Q 9/30/2024
6302024725202410-Q 6/30/2024
3312024502202410-Q 3/31/2024
12312023222202410-K 12/31/2023
93020231026202310-Q 9/30/2023
6302023727202310-Q 6/30/2023
3312023504202310-Q 3/31/2023
12312022223202310-K 12/31/2022
93020221027202210-Q 9/30/2022
6302022728202210-Q 6/30/2022
3312022428202210-Q 3/31/2022
12312021217202210-K 12/31/2021